Our data showed that STAT3 could bind to the CD155 promoter and IL-22 treatment increased CD155 mRNA and protein expressions in HCC cells, and these effects were dramatically reversed by STAT3 knockdown. This evidence concerns the gene IL22 and hepatocellular carcinoma.